British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Otsuka Pharmaceuticals says that its subsidiaries Otsuka Precision Health, Inc. (OPH) and Click Therapeutics (Click) have launched Rejoyn (developed as CT-152). 19 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
At a cool $1 billion, the venture round secured by AI group Xaira ranks as the second-biggest raise in biotech history. In the drug discovery space, this financing is dwarfed only by Altos Lab’s $3 billion, amassed back in 2021. 14 May 2024
Ian Churcher, vice president of drug discovery at BenevolentAI, argues that pharma needs to embrace artificial intelligence (AI) to solve the issues which underlie the stagnation of drug discovery, in an Expert View piece. 27 April 2018
The rising cost of drug development, growing need for medicines with an aging population and the greater prevalence of chronic conditions, political uncertainty – many factors suggest that the problem of pricing drugs affordably is not about to away any time soon. 24 April 2018
Mindful that integrating model-informed drug development (MIDD) into more drug applications and advancing its use are US Food and Drug Administration’s (FDA) goals under the Prescription Drug User Fee Amendments of 2017, the agency has stepped up its publicizing of the potential benefits to drugmakers. 20 April 2018
Business, technical, and financial incentives are driving the rapid adoption of cloud-based, commercially available solutions in pharmaceutical research and operations, writes Frank Lin, consultant at Halloran Consulting Group, in an Expert View piece. 27 March 2018
Deals with tech companies are almost seen as essential in pharma today as they consider how to combat challenges such as rising development costs, but rarely is the need for these collaborations spelt out so clearly as it was when two Japanese firms announced a collaboration on Monday. 26 March 2018
Harnessing digital technologies could unlock £22 billion ($30.1 billion) for UK pharma companies over the next decade, according to Accenture. 13 March 2018
In the second of two Expert View columns to whet the appetite for the eyeforpharma Barcelona event in March, Sanofi’s Chief Data Officer (CDO), Milind Kamkolkar, expounds the possibilities of digital and the role of the CDO in this burgeoning landscape. 31 January 2018
In a highly informative and useful Expert View piece, Heather Longden, senior marketing manager for informatics regulatory compliance at the analytical laboratory instrument and software company Waters Corporation, provides insights into the vital role data integrity plays when it comes to analytical testing for drug development. 26 January 2018
Andrew Rut, chief executive of MyMeds&Me, a provider of adverse event and product quality capture software, considers in an Expert View piece how pharma’s ability to run efficient clinical trials is in danger of being compromised by GDPR and a hardening of attitudes on data privacy globally. 9 January 2018
In an area like oncology, innovation is needed not just with the end product, but in the way that researchers get there, finds Rik Van Mol, vice president of R&D strategy at software provider Veeva Systems, in an Expert View piece looking at a leading cancer charity’s modernization of clinical operations. 15 November 2017
As many as 97% of life science companies expect to use more clinical data from a wider variety of sources over the next three years to make faster, more accurate decisions during trials, according to new research from Tufts Center for the Study of Drug Development. 7 November 2017
Bayer has entered into a strategic partnership with the healthcare division of Chinese tech company Alibaba Group, giving the German firm access to large amounts of customer data from the Alibaba platform. 23 October 2017
German life sciences company Merck KGaA on Sunday became the latest pharma major to back the big data revolution that some believe will transform healthcare. 11 September 2017
When facing an illness, one of the first things that patients and caregivers do is go online for information, writes Dawn Lacallade, chief social strategist and pharma practice lead at social media specialist LiveWorld, in an Expert View piece. 15 August 2017
Twenty-first century data is providing the data-heavy pharma industry with a modern dilemma: how to preserve corporate information when technological development is accelerating so fast, writes Dominic Johnstone, head of information management services at Crown Records Management. 1 August 2017
In an Expert View piece, Annie Sullivan, director of corporate social media at Anglo-Swedish pharma major AstraZeneca, discusses the company’s novel approach of being 'a better social media citizen' and how its adoption of this strategy at the ASCO Annual Meeting in 2017 may help evolve the role of pharma on social media. 31 July 2017